Kymriah (Tisagenlecleucel) CAR-T Denied: Appealing ALL and DLBCL Coverage Decisions

Kymriah (tisagenlecleucel) is an FDA-approved CAR-T (chimeric antigen receptor T-cell) therapy for B-cell acute lymphoblastic leukemia (ALL) in patients up to 25 years old who have relapsed or refractory disease, and for adults with relapsed or refractory large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. CAR-T therapy represents a fundamentally different treatment approach — the patient's own T-cells are collected, genetically engineered to target cancer cells, and re-infused. Costs range from $475,000 to $500,000 for the cell therapy product alone, and the full treatment episode significantly exceeds this. Insurance denials, while serious, are often reversible.

Why Kymriah Gets Denied

Eligibility and line of therapy disputes. For DLBCL, Kymriah is approved for patients who have received at least two prior lines of systemic therapy. Insurers sometimes deny when they argue that certain prior treatments don't count as separate "lines" of therapy, or when the sequence of prior treatments is not clearly documented.

Age restriction for ALL. The ALL indication covers patients up to 25 years of age. Denials for patients near this age boundary sometimes occur. Additionally, for pediatric ALL, the patient must have relapsed or refractory disease — definitions that can be disputed if the clinical record is not explicit about response to prior therapy.

Center of excellence requirement. CAR-T therapies must be administered at certified facilities. Kymriah is only available through the KYMRIAH REMS program at authorized treatment centers. If the requesting facility is not certified, the insurer will deny. Ensure the treating oncology center is REMS-certified before submitting the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization.

Performance status requirements. Clinical trials for Kymriah enrolled patients with ECOG performance status 0–2. Some insurers apply these enrollment criteria as coverage restrictions, denying patients with ECOG 3 or higher. However, the FDA label does not include a performance status cutoff, and expert oncologists regularly treat appropriate patients outside strict trial performance thresholds.

Bridging therapy coverage. Between apheresis (cell collection) and re-infusion (which typically takes 3–4 weeks for manufacturing), patients may require bridging chemotherapy to control rapidly progressing disease. Insurers sometimes deny bridging therapy either as separate from the CAR-T authorization or pending the final cell therapy approval. Bridging therapy should be included in the same prior authorization request as the CAR-T procedure.

Building a Kymriah Appeal

Document the line of therapy history precisely. For DLBCL, list each prior line of treatment:

• Line 1: drug regimen name (e.g., R-CHOP), cycle count, response achieved (CR/PR/SD/PD), date of progression
• Line 2: drug regimen, cycle count, response, date of progression
• Confirm that each was a separate treatment decision following disease progression or relapse

Establish refractory or relapsed status clearly. "Refractory" means no response to a treatment regimen. "Relapsed" means initial response followed by disease recurrence. The clinical notes should explicitly use these terms with supporting pathology, imaging, and/or bone marrow biopsy results.

Address the REMS/center certification. Confirm in the prior authorization that the treatment will occur at a certified Kymriah treatment center and provide the center's certification documentation if requested.

For ALL patients near age 25. The FDA approved Kymriah for patients "up to and including 25 years of age." If your patient is 25 at the time of treatment, confirm the exact FDA language is cited in the appeal — some insurer policies state "under 25" which is incorrect.

Expedited review is mandatory. For leukemia and lymphoma patients, the standard 30-day prior authorization timeline is clinically unacceptable. Request expedited/urgent review citing active malignancy with progressive disease. Most state laws require a 72-hour decision for expedited reviews in life-threatening conditions.

When the Insurer Proposes Alternatives

If the insurer attempts to substitute Yescarta (axicabtagene ciloleucel) for Kymriah or vice versa, these are distinct CAR-T products with different FDA indications, manufacturing processes, and toxicity profiles. They are not interchangeable. Your oncologist's letter should explain which product is appropriate for your specific cancer type, prior treatment history, and clinical situation.

Fight Back With ClaimBack

CAR-T denials carry some of the highest stakes in all of oncology — this may be the patient's last treatment option. ClaimBack builds precise, urgency-appropriate appeals for CAR-T coverage disputes.

Start your Kymriah appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?